# Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

> **NCT01051570** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 26 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** RAD 001
- **DRUG:** prednisone
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01051570
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051570, "Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01051570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*